Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pilot crossover study of amifampridine phosphate in MuSK antibody-positive myasthenia gravis
2015-003127-62Phase 2Terminated
- Sponsor
- Carlo Besta Neurological Institute
- Start
- Mar 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of amifampridine in Muscle-Specific Tyrosine Kinase Antibody-Positive Myasthenia Gravis (MuSK-MG) (2 arms), sponsored by Carlo Besta Neurological Institute. Primary endpoint: Incidence of TEAEs and SAEs. Started Mar 2017; status: terminated.
02
Drugs
amifampridine
03
Conditions
Muscle-Specific Tyrosine Kinase Antibody-Positive Myasthenia Gravis (MuSK-MG)
Beyond the preview
Go deeper on 2015-003127-62.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-003127-62.